Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 3 · newest first

  1. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directionsJournal of Hematology & Oncology · 2024
  2. Ponatinib‐review of historical development, current status, and future researchAmerican Journal of Hematology · 2024
  3. Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?Expert Review of Hematology · 2024
  4. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaJAMA · 2024
  5. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous diseaseBritish Journal of Haematology · 2024
  6. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation studyLeukemia & lymphoma/Leukemia and lymphoma · 2024
  7. Outcomes and genetic dynamics of acute myeloid leukemia at first relapseHaematologica · 2024
  8. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaCancer · 2024
  9. Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  10. Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  11. Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  12. Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  13. Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  14. Supplemental Figure 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  15. Supplemental Figure 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  16. Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  17. Supplemental Figure 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  18. Data from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  19. Supplemental Table 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  20. Supplemental Table 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  21. Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  22. Supplemental Table 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  23. Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  24. Supplemental Table 3 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  25. Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax2024
  26. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMMLDeleted Journal · 2024
  27. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLBlood · 2024
  28. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemiaAmerican Journal of Hematology · 2024
  29. Abstract 3400: Single-cell proteogenomics analysis of AML samples treated with decitabine and venetoclax reveals divergent treatment escape mechanismsCancer Research · 2024
  30. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmBlood Advances · 2024
  31. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasmsCancer Medicine · 2024
  32. Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trialAmerican Journal of Hematology · 2024
  33. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancerFrontiers in Hematology · 2024
  34. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndromeCancer · 2024
  35. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemiaAmerican Journal of Hematology · 2024
  36. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus VenetoclaxClinical Cancer Research · 2024
  37. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase InhibitorsJournal of the National Comprehensive Cancer Network · 2024
  38. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsLeukemia · 2024
  39. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AMLJournal of Clinical Oncology · 2024
  40. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialBlood Advances · 2024
  41. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid LeukemiaClinical Lymphoma Myeloma & Leukemia · 2024
  42. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxBlood Advances · 2023
  43. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL2023
  44. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patientsLeukemia & lymphoma/Leukemia and lymphoma · 2023
  45. Early mortality after chemotherapy as a quality indicator—the leukemia perspectiveBlood Cancer Journal · 2023
  46. Phase 1/2 study of CPX ‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agentsBritish Journal of Haematology · 2023
  47. Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line TherapyBlood · 2023
  48. CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib StudyBlood · 2023
  49. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up DataBlood · 2023
  50. Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)Blood · 2023